Video library
Real-world discussions with ECPs and patients
The MIEBO Experience
Find out how MIEBO helped real patient, Rahnee, manage her evaporative DED so she could continue her active lifestyle more comfortably.
The MIEBO Difference
Find out what makes MIEBO different and why Dr. Marc Bloomenstein OD, FAAO, chooses it for his patients with evaporative DED.
Peer Perspectives
Eye to Eye: The MIEBO MOA
See what leading eye care professionals have to say about evaporative DED and how MIEBO can help.
Talking to Patients About MIEBO With Dr. McGee
Listen to Selina McGee, OD, FAAO, share how she sets expectations when introducing patients to MIEBO.
Talking to Patients About MIEBO With Dr. Gupta
Listen to Preeya Gupta, MD, share how she educates her patients on proper administration of MIEBO.
Key Perspectives on MIEBO: Efficacy
Hear eye care experts discuss the results of MIEBO on the signs and symptoms of DED—supported by 2 pivotal trials.
Key Perspectives on MIEBO: Evaporation—An Unmet Need
Listen to eye care experts explore MIEBO and its role in addressing tear evaporation, a previously unmet need in DED.
Key Perspectives on MIEBO: Excellent Tolerability
Hear eye care experts share their perspectives on the excellent tolerability of MIEBO.
Key Perspectives on MIEBO: Patient Stories
Gain insights into real patient experiences with MIEBO from eye care experts.
Key Perspectives on MIEBO: Unique Features and MOA
Listen to eye care experts discuss MIEBO—the only Rx eye drop for DED that directly targets tear evaporation.
INDICATION
MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
- MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
- Instruct patients to instill one drop of MIEBO into each eye four times daily
- The safety and efficacy in pediatric patients below the age of 18 have not been established
- The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information for MIEBO.
You are now leaving MIEBO-ECP.COM
You are now leaving the MIEBO ECP website and are going to a website that Bausch + Lomb does not operate and to which Bausch + Lomb’s Privacy Policy does not apply.
Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to visit and does not endorse or monitor any content on such website.
INDICATION AND IMPORTANT
SAFETY INFORMATION
INDICATION
MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
- MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
- Instruct patients to instill one drop of MIEBO into each eye four times daily
- The safety and efficacy in pediatric patients below the age of 18 have not been established
- The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full prescribing Information for MIEBO.